Spasic, Maja Vujic; Maass, Thorsten; Lai, Dilay et al.
OVER-EXPRESSION OF HEPATIC SMAD7 IN MICE CAUSES HEMOCHROMATOSISAMERICAN JOURNAL OF HEMATOLOGY. Bd. 88. H. 5. 2013 S. E37-E37
Koschny, R.; Schott, E.; Galle, P. R. et al.
Overall survival of specific HCC patient subgroups in prospective, non-interventional INSIGHT study treated with sorafenibEUROPEAN JOURNAL OF CANCER. Bd. 49. 2013 S. S623-S623
Heemann, Uwe; Lutz, Jens
Pathophysiology and treatment options of chronic renal allograft damageNEPHROLOGY DIALYSIS TRANSPLANTATION. Bd. 28. H. 10. 2013 S. 2438-2446
Bockhorn, Maximilian; Lohse, Ansgar W.; Izbicki, Jacob R.
Periinterventional Coagulation ManagementVISZERALMEDIZIN. Bd. 29. H. 5. 2013 S. 264-265
Olson, S.; Baron, K.; Riggs, M. et al.
PHARMACOKINETIC MODELLING OF THE RELATIONSHIP BETWEEN SUSTAINED VIROLOGICAL RESPONSE AND PLASMA CONCENTRATIONS OF FALDAPREVIR OR BI-207127 IN HCV GT1-INFECTED PATIENTS IN SOUND-C2JOURNAL OF HEPATOLOGY. Bd. 58. 2013 S. S492-S493
de Dosso, S.; Fiedler, W.; Gianni, L. et al.
PHASE I CLINICAL AND PHARMACOLOGICAL STUDY OF CETUGEX, A NOVEL ANTI-EGFR MONOCLONAL ANTIBODY WITH AN OPTIMIZED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITYANNALS OF ONCOLOGY. Bd. 24. 2013 S. 8-8
Hoehler, T.; von Wichert, G.; Schimanski, C. et al.
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205BRITISH JOURNAL OF CANCER. Bd. 109. H. 6. 2013 S. 1408-1413
Dellas, Kathrin; Hoehler, Thomas; Reese, Thomas et al.
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancerRADIATION ONCOLOGY. Bd. 8. 2013
Wagner, Andrej; Kiesslich, Tobias; Neureiter, Daniel et al.
Photodynamic therapy for hilar bile duct cancer: clinical evidence for improved tumoricidal tissue penetration by temoporfinPHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES. Bd. 12. H. 6. 2013 S. 1065-1073
Hiepe, F.; Fischer-Betz, R.; Schwarting, A.
Post-hoc Analysis of the Effects of Belimumab on Musculoskeletal Organ Manifestations in BILAG in the Phase-3-Trials with BelimumabZEITSCHRIFT FUR RHEUMATOLOGIE. Bd. 72. 2013 S. 142-143